The post ‘The Worst Is Behind Us’: Bitcoin Market Conditions Mirror FTX Bottom, Analysts Say appeared on BitcoinEthereumNews.com. In brief A bottom may be formingThe post ‘The Worst Is Behind Us’: Bitcoin Market Conditions Mirror FTX Bottom, Analysts Say appeared on BitcoinEthereumNews.com. In brief A bottom may be forming

‘The Worst Is Behind Us’: Bitcoin Market Conditions Mirror FTX Bottom, Analysts Say

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

In brief

  • A bottom may be forming for Bitcoin amid its monthslong rout, K33 analysts said.
  • Technical indicators have paralleled the collapse of FTX, they wrote.
  • The market’s defensive posture is “atypical,” K33’s Vetle Lunde said.

Bitcoin has come under significant pressure in recent months, but there are signs that a bottom may be forming for the digital asset despite a backdrop of geopolitical instability, according to analysts at crypto research and brokerage firm K33.

As the U.S.-Israel war on Iran raged on for a fifth day, the analysts wrote in a Wednesday note that Bitcoin is showing signs of relative stability, leading them to determine that the most intense period of selling pressure has likely passed amid Bitcoin’s months-long swoon.

“The worst is behind us; now we wait,” they wrote. “However, bottoming regimes in BTC have typically been slow, and patience has been a necessary virtue.”

Bitcoin recently changed hands around $73,036, a more than 7% increase over the past day, according to CoinGecko. It remained 42% down from its all-time high of $126,000 in October.

K33 Head of Research Vetle Lunde cited technical indicators including Bitcoin’s weekly relative strength index, or RSI, which fell to 26.84 last week, its lowest level since July 2022. The indicator serves as a gauge for Bitcoin’s momentum based on the speed and magnitude of price changes, mirroring oversold conditions that emerged during a series of blowups among crypto lenders that year.

Those failures preceded the collapse of crypto exchange FTX, which marked the bottom for Bitcoin’s route in 2022. As Bitcoin has fallen in recent weeks, Velte noted that Bitcoin posted back-to-back days where trading volumes exceeded 95% of those on record. During bear markets, that has only happened once: when FTX filed for bankruptcy.

Beyond that, Lunde pointed to derivatives, where market participants have been “willing to pay a chunky premium for bearish bets” to protect against further price drops in perpetual futures markets that maintain price alignment with Bitcoin through periodic payments.

With regards to options, Lunde noted that so-called skews—which compare the cost of bearish “puts” versus bullish “calls”—jumped to levels only witnessed during the most catastrophic market collapses of 2022, including the fall of FTX and the Terra crash. Lunde described “extreme impulses of market stress” as an encouraging sign for bottoms to form.

K33’s report acknowledged that no indicator is foolproof, but history suggested “an overwhelming concentration of bets in one direction for BTC tends to be followed by BTC moving in exactly the opposite direction.”

Lunde echoed that sentiment in an interview with Decrypt, but he described the latest sell-off as relatively orderly compared to the chaos that rattled crypto prices years ago. Nonetheless, he viewed the defensive position in the crypto market as “atypical.”

“It is something that, in the past, has been associated with global bottoms,” Lunde told Decrypt. “Bitcoin has a tendency to do the unexpected.”

Daily Debrief Newsletter

Start every day with the top news stories right now, plus original features, a podcast, videos and more.

Source: https://decrypt.co/359970/worst-behind-us-bitcoin-market-conditions-mirror-ftx-bottom-analysts

Market Opportunity
Black Mirror Logo
Black Mirror Price(MIRROR)
$0.001303
$0.001303$0.001303
+1.24%
USD
Black Mirror (MIRROR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09